News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
TALAPRO-2: Miloš Grujić highlights improved quality of life with Talazoparib + Enzalutamide in mCRPC
Miloš Grujić//LinkedIn
Apr 15, 2025, 13:29

TALAPRO-2: Miloš Grujić highlights improved quality of life with Talazoparib + Enzalutamide in mCRPC

Miloš Grujić, Head of Department of the subspecialist cabinets at the Center for Radiation Oncology at the University Clinical Center Kragujevac, on LinkedIn:

“New Patient-Reported Outcomes from TALAPRO-2

In the latest results published in The Lancet Oncology, talazoparib + enzalutamide demonstrated a significant delay in quality of life deterioration for men with HRR-deficient metastatic castration-resistant prostate cancer (mCRPC).

Median time to GHS/QoL deterioration:

  • 27.1 months vs 19.3 months
  • HR 0.69 (95% CI: 0.49–0.97), p=0.032

This supports the dual aim of treatment:
Prolonging survival while preserving quality of life.
Incorporating patient-reported outcomes is critical in our evolving standards for mCRPC care.

The study also suggested improved outcomes in urinary and pain symptom control, reinforcing the clinical relevance of durable disease control with PARP + ARPI combinations.

Miloš Grujić

First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial

Authors: Andre P Fay et al.

Miloš Grujić

More posts featuring Miloš Grujić on OncoDaily.

Alexander Niyazov André P. Fay Arun A. Azad cancer Curtis Dunshee Cynthia G Healy Enzalutamide Fred Saad Jae Young Joung Jan Oldenburg Jane Chang Joan Carles Karim Fizazi mCRPC Miloš Grujić Neal D. Shore Neeraj Agarwal Nobuaki Matsubara OncoDaily Oncology Paul Cislo Peter C.C. Fong Robert J Jones Stefanie Zschäbitz TALAPRO-2 Talazoparib Ugo de Giorgi
Special Coverage
Science
Apr 15, 2025, 13:29
TALAPRO-2: Miloš Grujić highlights improved quality of life with Talazoparib + Enzalutamide in mCRPC
Blog
Apr 15, 2025, 13:28
Joshua Brody: Combining lymphoma immunotherapy with Standard of Care
Blog
Apr 15, 2025, 13:18
Hidehito Horinouchi: Afatinib in patients with solid tumors with neuregulin1 (NRG1) fusions
Blog
Apr 15, 2025, 13:09
Fumiko Ladd Chino: Our ongoing work to share freely accessible, cutting-edge, clinically relevant science with the world
Blog
Apr 15, 2025, 13:06
Petros Grivas: Great to spend time at 40 years of Hellenic Society of Medical Oncology
Blog
Apr 15, 2025, 13:00
Join the upcoming bi-weekly Cancer and Aging Research Group (CARG) meeting
Insight
Apr 15, 2025, 12:48
Yvonne Bombard presented on Mitigating Disparities in Hereditary Cancer Genetics at 2025 OMPRN Webinar
Blog
Apr 15, 2025, 12:44
CancerWorld Cover Conversations - A chance to connect with the giants in the field of oncology
Blog
Apr 15, 2025, 12:42
Fumiko Ladd Chino: Projected Lifetime Cancer Risks From Current Computed Tomography Imaging
Blog
Apr 15, 2025, 12:34
Chandler Park: Great privilege to advocate for cancer patients at the 2025 ASCO Advocacy Summit
Societies
Apr 15, 2025, 12:34
American Cancer Society Cancer Action Network launched 2025 annual Giving Week
Blog
Apr 15, 2025, 12:29
Wafaa M Rashed: Mutaz Mohamed on the urgent need to expand affordable genetic testing across African nations